{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T01:12:46Z","timestamp":1648948366193},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,15]]},"DOI":"10.1097\/qad.0000000000000627","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T16:20:30Z","timestamp":1429892430000},"page":"987-988","source":"Crossref","is-referenced-by-count":1,"title":["Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes"],"prefix":"10.1097","volume":"29","author":[{"given":"Ana B.","family":"Abecasis","sequence":"first","affiliation":[]},{"given":"Kristel","family":"van Laethem","sequence":"additional","affiliation":[]},{"given":"Kristof","family":"Theys","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-18-20210130","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1586\/14787210.2013.844649","article-title":"HIV-1 genetic variation and drug resistance development.","volume":"11","author":"Megens","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R2-18-20210130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QAD.0000000000000140","article-title":"Occurrence of etravirinerilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy.","volume":"3","author":"Crawford","year":"2014","journal-title":"AIDS"},{"key":"R3-18-20210130","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0000000000000350","article-title":"Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.","volume":"15","author":"Crawford","year":"2014","journal-title":"AIDS"},{"key":"R4-18-20210130","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1089\/aid.2009.0302","article-title":"Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.","volume":"11","author":"Tambuyzer","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R5-18-20210130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies.","volume":"4","author":"Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"R6-18-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.","volume":"1","author":"Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-18-20210130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.","volume":"1","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R8-18-20210130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.aids.0000216363.36786.2b","article-title":"HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes.","volume":"5","author":"Rhee","year":"2006","journal-title":"AIDS"},{"key":"R9-18-20210130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.04.001","article-title":"E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.","volume":"107","author":"Sluis-Cremer","year":"2014","journal-title":"Antiviral Res"},{"key":"R10-18-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/08892220050042765","article-title":"Presence of 2,5-Bis-O-(tert-butyldimethylsilyl)-3-spiro-5-(4-amino-1,2-oxath iole-2,2-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.","volume":"9","author":"Van Laethem","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R12-18-20210130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/cid\/cit430","article-title":"Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.","volume":"7","author":"Gatanaga","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R13-18-20210130","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/jac\/dku256","article-title":"Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France.","volume":"11","author":"Jeulin","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R14-18-20210130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.","volume":"16","author":"Meynard","year":"2002","journal-title":"AIDS"},{"key":"R15-18-20210130","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation.","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R16-18-20210130","doi-asserted-by":"crossref","first-page":"e61436","DOI":"10.1371\/journal.pone.0061436","article-title":"Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response.","volume":"8","author":"Vercauteren","year":"2013","journal-title":"PLoS One"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0000000000000627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:11:46Z","timestamp":1620969106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201505150-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000000627","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,15]]}}}